Frédéric Selle

11PUBLICATIONS
106CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jan 15, 2026
ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial.

Guillaume Beinse, Valerie Taly, Alexandra Leary

|Jan 08, 2026
ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial.

Félix Blanc-Durand, Catherine Genestie, Sergey Nikolaev

|Dec 03, 2025
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.

Philipp Harter, Frederik Marmé, Andrés Redondo

|Sep 04, 2025
Clinical outcome of advanced or recurrent endometrial carcinoma treated with chemotherapy: a French observational retrospective cohort: the ENDOVIE study.

Jerome Alexandre, Philippe Boudier, Elise Lavit

|Aug 26, 2025
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial.

Florence Joly, Alexandra Leary, Isabelle Ray-Coquard

|May 28, 2025
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 Consortium.

Nicole Concin, Ioana Braicu, Pierre Combe

Pageof 2

Frequent Collaborators

6 joint publications

Isabelle Ray-Coquard

5 joint publications

Jérôme Alexandre

5 joint publications

Florence Joly

4 joint publications

Michel Fabbro